SATURN

Principal Investigator:
Daniel Lee, MD (Bay Med)
William Felten, MD (Midland)
Rao Gudipati, MD (St. Marys)

Sub-Investigators:
Stephen Mattichak, MD                         Gregory Pellizzon, MD
John Collins, MD                                  Shiraz Shariff, MD
Alok Maheshwari, MD                           Manoj Sharma, MD
Kondaramvalappil Ravindran, MD           Umesh Badami, MD

Sponsor:
Astra Zeneca

Study Purpose:
A 104-week, randomized, double-blind, parallel group, multi-center Phase IIIb study comparing the effects of treatment with rosuvastatin 40 mg or atorvastatin 80 mg on atherosclerotic disease burden as measured by intravascular ultrasound in patients with coronary artery disease: the SATURN trial.

Objective:
To compare the effects of 40 mg of rosuvastatin to 80 mg of atorvastatin, taken daily for two years, on the progression of this disease, and to determine if these therapies will reduce the atheroma (fatty deposits) in your arteries.

Status:
Active enrollment

If you have any questions, please feel free to contact the coordinators, and they will be happy to answer any questions you have regarding this study.

<< Back